Please login to the form below

Not currently logged in
Email:
Password:

Roche and Covagen collaborate

Roche has entered into a collaboration agreement with Covagen, a Swiss biotechnology company

Roche has entered into a collaboration agreement with Covagen, a Swiss biotechnology company that is developing next generation protein drugs for the treatment of diseases using Fynomer technology at the Institute of Pharmaceutical Sciences at ETH Zurich. 

Covagen's innovative platform comprises a novel single domain protein scaffold, which - in analogy to antibodies - can be engineered to yield high affinity binding proteins (Fynomers) that can be used for therapeutic applications. Covagen filed patent applications to protect its drug development platform, allowing it to become active in a new field of intellectual property, which is a significant advantage compared with the antibody field that has been widely claimed already.

Under the terms of the agreement with Roche, Covagen will use its protein engineering technology to isolate Fynomers binding to undisclosed targets provided by Roche. Fynomers delivered by Covagen will be further tested and evaluated by Roche to discover potential new treatments for patients with unmet medical needs. 

Dr Dragan Grabulovski, CSO and co-founder of Covagen commented: "This collaboration with Roche represents a further step to establish Covagen's Fynomers as new binding proteins for a variety of applications in drug discovery."

The financial terms of the collaboration agreement have not been disclosed.

22nd June 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cello Health Insight

Cello Health Insight is the global market research arm of Cello Health. With 35 years’ sector experience, we specialise in...

Latest intelligence

segmentation_pie_thumb.jpg
If you’re not thinking segmentation, you’re not thinking
Having a background in market research I’ve been lucky to work on a number of customer segmentations in my time but working in creative communications it is still too rare...
Improving Outcomes in the Treatment of Opioid Dependence Highlights Report
The 16th annual ‘Improving Outcomes in the Treatment of Opioid Dependence’ (IOTOD)conference took place at the Hilton Madrid Airport hotel on 15–16 May 2018....
Londonvelophobia (fear of cycling in London) – debunked
...

Infographics